Page last updated: 2024-12-06
kitazine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
kitazine: see also record for kitazin P; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 25834 |
SCHEMBL ID | 7174164 |
MeSH ID | M0096063 |
Synonyms (37)
Synonym |
---|
5115-94-6 |
nsc49723 |
o,o-diethyl s-benzyl thiophosphate |
13286-32-3 |
ricide |
s-benzyl o,o-diethyl phosphorothioate |
phosphorothioic acid,o-diethyl s-(phenylmethyl) ester |
kitazin |
wln: 2opo&o2&s1r |
nsc-49723 |
o,o-diethyl s-benzyl phosphorothioate |
s-benzyl-o,o-diethylester kyseliny thiofosforecne [czech] |
kitazine |
phosphorothioic acid, o,o-diethyl s-(phenylmethyl) ester |
brn 2214893 |
nsc 49723 |
ritacin-p [russian] |
phosphorothioic acid, s-benzyl o,o-diethyl ester |
benzyl ethyl phosphorothioate ((phch2s)(eto)2po) |
EBP , |
diethoxyphosphorylsulfanylmethylbenzene |
4-06-00-02763 (beilstein handbook reference) |
79bpy4n2dk , |
s-benzyl-o,o-diethylester kyseliny thiofosforecne |
unii-79bpy4n2dk |
ritacin-p |
CCG-2098 |
AKOS015888420 |
SCHEMBL7174164 |
DTXSID0074502 |
sr-01000195999 |
SR-01000195999-1 |
isoprobenphos |
diethyl (benzylsulfanyl)phosphonate |
ebp;kitazin 48ec; nsc 49723;ricid |
ebp (insecticide) |
kitagine |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 23.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.38) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |